

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



April 6, 2026

Company name:	Mochida Pharmaceutical Co., Ltd.
Name of representative:	Naoyuki Mochida, Representative Director, President
(Securities code:	4534 Prime Market, TSE)
Inquiries:	Kenichi Miyamoto, Head of Finance & Accounting Department
(Telephone:	+81-3-3358-7211)

Notice Concerning Determination of Offering Price and Other Matters

Mochida Pharmaceutical Co., Ltd. (the “Company”) hereby announces that the offer price and other matters have been determined today as follows in relation to a secondary offering of shares of common stock of the Company which was resolved at a meeting of the Board of Directors held on March 30, 2026.

1. Secondary Offering of Shares (Offering by way of Purchase and Underwriting by the Underwriter)

- | | |
|---|------------------------|
| (1) Offer price: | 3,331 yen per share |
| (2) Total offer price: | 3,842,641,600 yen |
| (3) Subscription price: | 3,193.60 yen per share |
| (4) Total amount of the subscription price: | 3,684,136,960 yen |
| (5) Delivery date: | Monday, April 13, 2026 |

(Note) The underwriters will purchase and underwrite the shares at the subscription price and conduct the secondary offering at the offer price.

2. Secondary Offering of Shares (Offering by way of Over-allotment)

- | | |
|-------------------------------------|------------------------|
| (1) Number of shares to be offered: | 173,000 shares |
| (2) Offer price: | 3,331 yen per share |
| (3) Total offer price: | 576,263,000 yen |
| (4) Delivery date: | Monday, April 13, 2026 |

Disclaimer: This document has been prepared for the purpose of announcing to the public certain matters relating to the secondary offering of shares of common stock of the Company, and not for the purpose of soliciting investment or similar activities whether in or outside Japan. When making an investment, investors should carefully review the prospectus for the secondary offering of shares, and amendments thereto (if any) prepared by the Company and make the investment based on their own judgement. The prospectus for the secondary offering of shares, and amendments thereto (if any) can be obtained from the underwriter. This document does not constitute an investment solicitation for any securities for sale. This document does not constitute an offer of investment in nor solicitation for purchase securities within the United States or elsewhere. The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933 or any relevant securities law of any state. The securities may not be offered or sold in the United States absent registration or an exemption from registration requirements under the U.S. Securities Act of 1933. No offers of securities for sale in the United States will be made in connection with the above-mentioned transactions.